anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Placebo and nocebo effects have been well documented for nearly two centuries. However, research has only relatively recently begun to explicate the neurobiological underpinnings of these phenomena. Similarly, research on the broader social implications of placebo/nocebo effects, especially within healthcare delivery settings, is in a nascent stage. Biological and psychosocial outcomes of placebo/nocebo effects are of equal relevance. A common pathway for such outcomes is the endogenous opioid system. This chapter describes the history of placebo/nocebo in medicine; delineates the current state of the literature related to placebo/nocebo in relation to pain modulation; summarizes research findings related to human performance in sports and exercise; discusses the implications of placebo/nocebo effects among diverse patient populations; and describes placebo/nocebo influences in research related to psychopharmacology, including the relevance of endogenous opioids to new lines of research on antidepressant pharmacotherapies.
Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
Itraconazole is predominantly metabolized in the liver. A pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100 mg dose of itraconazole as capsule. A statistically significant reduction in mean Cmax (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in chornic patients during long-term use of itraconazole. (See CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions and DOSAGE AND ADMINISTRATION.)
The invention provides a medical follow-up system and a follow-up method thereof, and relates to the technical field of follow-up. The system comprises a data server, a doctor end and a patient end. The data server is configured to integrate the follow-up information according to the follow-up requirements, establish follow-up control items, and collect medical record information associated with the follow-up control items. The doctor end comprises a follow-up plan entry module, a follow-up plan query module and a data detection module, wherein the follow-up plan query module is used for querying historical follow-up control items, and the follow-up plan entry module is used for entering preset follow-up control items, wherein the follow-up control items comprise follow-up patient basic information, follow-up time information and follow-up summary information. The patient side is arranged for viewing follow-up information through the data server and can fill out basic follow-up patient information. The medical follow-up system has the advantages of improving the user experience of patients, improving the working efficiency of follow-up personnel, reducing the purchasing cost and realizing intelligent integration.
Participants will learn about the study through flyers, e-mail, and social media (i.e. twitter and Facebook) which will describe the interventional nature of the study, the main eligibility criteria, and the researcher's contact information. Interested individuals will be asked to contact the researchers, who will then send an information sheet detailing the study procedure and what participation would involve. After reading the information sheet, interested individuals will be contacted by the researchers in order to confirm all eligibility criteria including diagnostic assessment. If these are met a PDF of the consent form will be sent to the participants, including information about their rights as participants and their ability to withdraw at any time without having to give a reason. Participants who sign the consent form will respond to the email with the attached document. Next, researchers will contact the participant to set an appointment to enter the lab for the first EEG recording. Before entering the lab, participants will be asked to complete a food diary and complete the complete a battery of questionnaires. The questionnaires include: 1) a demographic questionnaire, 2) eating disorders examination questionnaire, 3) food ratings test, 4) self-regulation of eating behaviour questionnaire for adults, 5) The negative urgency scale, 6) the adults eating behaviour questionnaire, 7) GAD-7, and 8) PHQ-9.

Upon participants' arrival to the lab, participants will be asked to complete the food rating task. Next, they will learn to complete the training tasks (i.e. food specific go/no-go and general go/no-go) and perform them during EEG recording. They will be offered the opportunity to ask questions relating to the task or the EEG at any time. Their weight will also be measured.

Participants will be asked to complete the training and complete food diaries every day for four weeks. The successful/ unsuccessful attempts at implementation intentions will be assessed weekly by a mentor. A researcher/clinician will discuss setting the implementation intention goals with the participant over email. At the end of the training, participants will enter the lab to re-complete the four tasks while researchers record brain activation using the EEG. They will also be asked to complete the food rating task again and their weight will be re-assessed. Before leaving, they will be asked to complete a feedback sheet in which they can express their experience with the training, in terms of facilitators and barriers and visual analogue scales that will ask participants to rate the acceptability, usefulness and level of burden experienced with training.

Participants will then be followed up at 1 month post-intervention; they will be asked to complete the battery of questionnaires used at baseline and post-intervention.
The present study was aimed at showing the importance of HPV DNA status and the clinical history of the patients required by the cytologist for accurate reporting. A total of 1250 symptomatic women who attended the gynaecology outpatient department of the Mahavir Cancer Sansthan and Nalanda Medical College, Patna, for pap smear examinations were screened and recruited for the study. Due to highly clinical symptoms out of the negative with inflammatory smears reported, one hundred and ten patients were randomly advised for biopsy and HPV 16/18 DNA analysis by a gynaecologist to correlate negative smears included in the study. Pap smear reports revealed that 1178 (94.24%) were negative for intraepithelial lesions (NILM) with inflammatory smears, 23 (1.84%) smears showed low-grade squamous intraepithelial lesions (LSIL), 12 (0.96%) smears showed high-grade squamous intraepithelial lesions, and 37 (2.96%) smears showed an atypical squamous cell of undetermined significance (ASC-US). A biopsy of 110 out of 1178 (NILM) patients revealed that 15 (13.63%) women had cervical cancer, 29 women had CIN I, 17 women had CIN II + CIN III, 35 women had benign cervical changes, and 14 women had haemorrhages. On the other hand, HPV 16/18 DNA was detected as positive in 87 out of 110. The high positivity of HPV in biopsied cases where frank cervical cancer and at-risk cancer were also observed in the negative smear-screened patients reveals that the HPV status and clinical history of the patients will be quite helpful to the cytologist for accurate reporting, and suggests that a negative HPV DNA result may be a stronger predictor of cervical cancer risk than a negative Pap test.
In recent years, diets of widely varying composition have been used in the treatment of obesity. While none of these diets has produced consistent, long-term weight loss, some individuals on virtually all types of diets do remarkably well. One explanation for this variation among individuals is differences in motivation and behavior. However, underlying biological differences may also play an important role. Previous work has identified insulin secretion (as quantified by serum insulin concentration at 30 minutes following a standard 75-gram oral glucose load) as an important biological determinant. This randomized-controlled, multi-center trial aims to test the hypothesis that insulin secretion will predict which type of diet will work best for each individual. A total of 160 obese young adults (18 to 40 years) will be assigned to one of two diets: low-fat (60% carbohydrate, 20% fat, 20% protein) or low-glycemic load (45% carbohydrate, 35% fat, 20% protein). Participants will be enrolled at two sites (Children's Hospital Boston or University of North Carolina-Chapel Hill) and assigned to diet groups according to baseline insulin secretion status. The protocol will include an intensive 6-month intervention period and a 12-month follow-up period. Registered dietitians will provide nutrition education and behavioral counseling during group workshops and scheduled telephone calls. In an effort to avoid confounding, close attention will be paid to control for treatment intensity, physical activity prescriptions, and behavioral methods between groups. The primary endpoint will be percent body fat by DXA scan. Secondary endpoints will include cardiovascular and diabetes risk factors. Repeated, 24-hour dietary and physical activity recall interviews will provide process data. Metabolomic profiling and molecular analysis of identified metabolites will be conducted to characterize phenotype and explore potential physiological mechanisms. A successful outcome of this work will inform the practice of "personalized" nutritional therapy, enhancing the ability to select the most efficacious weight loss diet for an individual based on underlying biological differences.
PROBLEM TO BE SOLVED: To easily and efficiently perform a review processing when image patterns are automatically classified by automatically classifying images and finding automatic classification results and the reliability of the automatic classification results, and then displaying the images on a review picture in the lowering order of the reliability of the automatic classification results. SOLUTION: An image input device 110 photographs an enlarged still picture of particles in urine. The photographed picture is classified by an image processor 120 by using image pattern recognition technology to obtain showing what kind of and how many particles urine per unit volume contains. The data are sent to a review device 200 through a communication means 300. The data include automatic classification results of the particle picture, the reliability of the automatic classification results, 2nd candidates for automatic classifications, particle picture, etc. Here, two kinds of data on the reliability of the classification results and the 2nd candidates for automatic classification are sent to display pictures in the lowering order of the reliability.
The invention discloses silver-carrying nanometer cod liver oil microemulsion and a low energy consumption preparation process thereof. The microemulsion is oil-in-water microemulsion; nanometer cod liver oil droplets are dispersed in a continuous water phase of the microemulsion, and the nanometer cod liver oil droplets contain nanometer silver particles. The silver-carrying nanometer cod liver oil microemulsion prepared in the invention is oil-in-water microemulsion in which nanometer silver particles are loaded and have a dispersion diameter less than 100 nm in a water phase. Other nutritional components like amino acids and oligosaccharide can also be added into the microemulsion so as to increase functions of the nanometer vitamin microemulsion, thereby forming a variety of application formulas with different functions. Since a nanometer cod liver oil disperse system contains nanometer silver particles, the microemulsion has broad spectrum antibiotic action. Therefore, the microemulsion in the invention not only can highly effectively supplement fat-soluble vitamins A and D needed by animals, but also has an effect of broad spectrum high efficiency bacteriostasis.
Described herein is a multi-functional polymeric material for use in inhibiting adhesion and immune recognition between cells and cells, cells and tissues, and tissues and tissues. One component of the polymeric material adsorbs well to cells or tissue, and the other component of the polymeric material does not adsorb well to tissues. A water-soluble polymer that does not bear charge (polynonion) and which is not poly(ethylene glycol) is used as the non-binding component. A water-soluble polymer that is positively charged at physiological pH (polycation) and which is not poly(L-lysine) is used as the tissue binding component. When the bi-functional polymeric material contacts a tissue, the tissue-binding component binds and thus immobilizes the attached non-binding component, which will then extend generally away from the tissue surface and sterically block the attachment of other tissues. The method and compositions are useful in inhibiting formation of post-surgical adhesions, protecting damaged blood vessels from thrombosis and restenosis, and decreasing the extent of metastasis of attachment-dependent tumor cells.
Personal sound amplification devices (PSADs) have recently become available to the public. PSADs serve a potentially important role in providing audibility of sounds for adults who find themselves having difficulty hearing and understanding speech in some daily living situations, but may not be candidates for traditional, high-amplification hearing aids. Despite hearing loss being a very common problem, few adults who could benefit from some level of amplification actually access the technology. Only approximately 1 in 7 adults (14%) over the age of 50 with a hearing loss using amplification. High cost is the most commonly cited reason for not wanting to try amplification, and indeed, hearing aids range from $1000 to $5000 each (i.e., per ear). PSADs range from $50-$600 each, and may provide a reasonable option for people who are not ready, or are unwilling, to wear a hearing aid. This project aims to examine the feasibility of a PSAD to provide audible and clear sound signal to adult listeners. The significance of this project is its potential to develop an option for individuals to take advantage of amplification and access sound to improve quality of life, who may not otherwise do so without this technology.
The invention concerns a compound corresponding to general formula (I) wherein, in particular: R¿2? represents a phenylmethyl or naphthylmethyl or cyclohexylmethyl radical, 2- and 3-pyridinylmethyl, substituted on the cycle in meta or para position by an acid group or an alkyl radical of the type (CH¿2?)¿n? (with n = 3 or 4) substituted in terminal position by an acid group; and R¿3? represents a hydrogen group or a linear or branched C¿1?-C¿4? alkyl or alkylcycloalkyl with a C¿3?-C¿6? cycloalkyl. The invention also concerns the use of a compound of general formula (I) for preparing a pharmaceutical composition for treating diseases related to proliferative processes, cancers and/or metastases.
PROBLEM TO BE SOLVED: To obtain the subject agent containing calcitonin or its salt as an active component, giving little injury to the gastric wall and mucosa compared with conventional nonsteroidal anti-inflammatory agent, having prolonged analgesic effect and usable in combination with the nonsteroidal anti-inflammatory agent. SOLUTION: This agent contains a calcitonin or its salt as an active component. The calcitonin is preferably [ASU<1-7> ] avian calcitonin of the formula (avicatonin), [ASU<1-7> ] eel calcitonin (elcatonin) and salmon calcitonin expressed by the chemical name of 1-butyric acid-7-(L-2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alaninecalcitonin (salmon). The agent is preferably administered by parenteral administration twice a week at a rate of 10-40 units per dose for adult in terms of the active component. The agent is prepared in the form of e.g. injection, rectal absorbing agent, percutaneous absorbing agent, transnasal absorbing agent, etc.
BACKGROUND: Gangrene and perforation are severe complications of acute appendicitis, associated with a higher mortality rate compared to uncomplicated appendicitis. Accurate preoperative identification of Gangrenous or perforated appendicitis (GPA) is crucial for timely surgical intervention.
METHODS: This retrospective multicenter study includes 796 patients who underwent appendectomy. Univariate and multivariate logistic regression analyses are used to develop a nomogram model for predicting GPA based on laboratory tests and computed tomography (CT) findings. The model is validated using an external dataset.
RESULTS: Seven independent predictors were included in the nomogram: white blood cell count, lymphocyte count, D-dimer, serum glucose, albumin, maximum outer diameter of the appendix, and presence of appendiceal fecalith. The nomogram achieved good discrimination and calibration in both the training and testing sets. In the training set, the AUC was 0.806 (95%CI: 0.763-0.849), and the sensitivity and specificity were 82.1% and 66.9%, respectively. The Hosmer-Lemeshow test showed good calibration (P = 0.7378). In the testing set, the AUC was 0.799 (95%CI: 0.741-0.856), and the sensitivity and specificity were 70.5% and 75.3%, respectively. Decision curve analysis (DCA) confirmed the clinical utility of the nomogram.
CONCLUSION: The laboratory test-CT nomogram model can effectively identify GPA patients, aiding in surgical decision-making and improving patient outcomes.
A method of treating an oral surface, particularly pellicle on the surface of teeth, with an oral treatment agent, comprising: (a) providing the oral treatment agent as molecules thereof having chemically bonded thereto at least one azlactone substituent moiety; (b) applying the azlactone-functionalised oral treatment agent to the oral substrate to effect reaction of the or each azlactone moiety with a or a respective nucleophilic reactive site (e.g. from a protein in the surface substrate layer) on the oral substrate; whereby the molecules of oral treatment agent are chemically bound to the oral substrate to impart their one or more cosmetic, pharmaceutical or therapeutic benefits thereto. The chemisorption resulting from the reaction of the azlactone group or groups with the oral substrate surface provides a significantly longer lasting oral benefit compared with conventional oral delivery systems. The novel azlactone-functionalised oral treatment agents, e.g. antistain agents, may be delivered from conventional compositions, e.g. toothpastes, mouthwashes, etc.
The invention provides an essential oil of Satureja montana with a high geraniol content, and use for treating greasy skin and/or the associated aesthetic defects. The present invention relates to an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-[Beta]-caryophyllene, in particular of Satureja montana L. ssp. variegata. The present invention also relates to the cosmetic use of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-[Beta]-caryophyllene, in particular of Satureja montana L. ssp. variegata, for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects. The invention also relates to a cosmetic composition comprising said oil, to a non-therapeutic cosmetic care and/or cleansing treatment process for greasy skin, and also to said essential oil as a dermatological agent
PURPOSE:The titled inhibitor having specifically high antibacterial action on bacteria of dental caries, and high safety, containing dihydroguaiaretic acid as an active ingredient. CONSTITUTION:The titled inhibitor containing dihydroguaiaretic acid shown by the formula as an active ingredient. The compound shown by the formula is contained in Machilus edulis K., a kind of Machilus thunbergii, Guaiacum officinale L., etc. A composition containing it has extremely high specificity to Streptococcus mutans, no reduction in growth prevention effect of bacteria caused by surface active agent, high safety, weak taste, and no physical disorder in the mouth. Since the inhibitor has bacteriostatic effect on bacteria of dental caries, and the sterilizing effect is mild, a solution, etc. of a solution of it in glycerin is preferably added to a food (e.g., chewing gum) in which dihydroguaiaretic acid can remain as long as possible.
Patients with cardiac arrhythmias develop increased rates of anxiety and depression. Atrial arrhythmias, such as paroxysmal atrial fibrillation (AF), and ventricular arrhythmias, such as those with implantable cardioverter defibrillators (ICD) are particularly at risk. While ICDs can be life saving, many patients (including those without prior psychiatric illness) develop elevated rates of anxiety and depression, particularly after receiving discharges (shocks) from the device. Treatments involving modulation of the breath have been shown to improve both psychological and cardiac outcomes in patients with AF. Since breathing modulation alters sympathetic balance, this may be a mechanism of the therapeutic effect. This study examines the impact of a breathing training intervention on cardiorespiratory sensations and anxiety in adults with atrial and ventricular cardiac arrhythmias.
Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or comatose condition. Loss of pallor, increase in toe temperature and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Reported studies indicate that when dopamine hydrochloride is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine hydrochloride has resulted in an increase in urine flow which in some cases reached normal levels. Dopamine hydrochloride may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of preexisting fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Concurrent administration of dopamine hydrochloride and diuretic agents may produce an additive or potentiating effect.